1
|
Banella S, Saraswat A, Patel A, Serajuddin ATM, Colombo P, Patel K, Colombo G. In Vitro Assessment of Cisplatin/Hyaluronan Complex for Loco-Regional Chemotherapy. Int J Mol Sci 2023; 24:15725. [PMID: 37958708 PMCID: PMC10647681 DOI: 10.3390/ijms242115725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 09/27/2023] [Accepted: 10/23/2023] [Indexed: 11/15/2023] Open
Abstract
Loco-regional chemotherapy is a strategy used to achieve more precise anticancer drug effect directly on tumor mass, while decreasing whole body exposure, which can lead to undesirable side effects. Thus, the loco-regional chemotherapy is conceptually similar to the targeted drug delivery systems for delivering chemotherapeutics to cancer cells in a certain location of the body. Recently, it has been demonstrated that a novel polymeric film containing the complex between cisplatin (cisPt) and hyaluronan (sodium salt of hyaluronic acid; NaHA) enhanced in vivo efficacy and safety of cisplatin (cisPt) by loco-regional delivery in pleural mesothelioma. Biologically, hyaluronic acid (HA) binds with the CD44 receptor, which is a transmembrane glycoprotein overexpressed by other cancer cells. Thus, administering both cisPt and hyaluronan together as a complex loco-regionally to the tumor site could target cancer cells locally and enhance treatment safety. A slight excess of hyaluronan was required to have more than 85% cisPt complexation. In cell monolayers (2D model) the cisPt/NaHA complex in solution demonstrated dose- and time-dependent cytotoxic effect by decreasing the viability of pancreatic, melanoma, and lung cell lines (they all express CD44). At the same concentration in solution, the complex was as effective as cisPt alone. However, when applied as film to melanoma spheroids (3D model), the complex was superior because it prevented the tumor spheroid growth and, more importantly, the formation of new cell colonies. Hence, cisPt/NaHA complex could work in preventing metastases loco-regionally and potentially avoiding systemic relapses.
Collapse
Affiliation(s)
- Sabrina Banella
- Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy; (S.B.); (G.C.)
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Aishwarya Saraswat
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Akanksha Patel
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Abu T. M. Serajuddin
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | | | - Ketan Patel
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Gaia Colombo
- Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy; (S.B.); (G.C.)
| |
Collapse
|
2
|
Prevention of cisplatin-induced nephrotoxicity by kidney-targeted siRNA delivery. Int J Pharm 2022; 628:122268. [DOI: 10.1016/j.ijpharm.2022.122268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Revised: 09/10/2022] [Accepted: 10/02/2022] [Indexed: 11/24/2022]
|
3
|
Choi AY, Singh A, Wang D, Pittala K, Hoang CD. Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma. Front Oncol 2022; 12:886430. [PMID: 35586499 PMCID: PMC9108281 DOI: 10.3389/fonc.2022.886430] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 04/04/2022] [Indexed: 11/13/2022] Open
Abstract
Multimodality therapy including surgical resection is the current paradigm in treating malignant pleural mesothelioma (MPM), a thoracic surface cancer without cure. The main limitation of all surgical approaches is the lack of long-term durability because macroscopic complete resection (R1 resection) commonly predisposes to locoregional relapse. Over the years, there have been many studies that describe various intrapleural strategies that aim to extend the effect of surgical resection. The majority of these approaches are intraoperative adjuvants. Broadly, there are three therapeutic classes that employ diverse agents. The most common, widely used group of adjuvants are comprised of direct therapeutics such as intracavitary chemotherapy (± hyperthermia). By comparison, the least commonly employed intrathoracic adjuvant is the class comprised of drug-device combinations like photodynamic therapy (PDT). But the most rapidly evolving (new) class with much potential for improved efficacy are therapeutics delivered by specialized drug vehicles such as a fibrin gel containing cisplatin. This review provides an updated perspective on pleural-directed adjuncts in the management of MPM as well as highlighting the most promising near-term technology breakthroughs.
Collapse
|
4
|
Carvalho SG, Silvestre ALP, Martins Dos Santos A, Fonseca-Santos B, Rodrigues WD, Palmira Daflon Gremião M, Chorilli M, Villanova JCO. Polymeric-based drug delivery systems for veterinary use: State of the art. Int J Pharm 2021; 604:120756. [PMID: 34058307 DOI: 10.1016/j.ijpharm.2021.120756] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 05/11/2021] [Accepted: 05/26/2021] [Indexed: 01/03/2023]
Abstract
One of the challenges to the success of veterinary pharmacotherapy is the limited number of drugs and dosage forms available exclusively to this market, due to the interspecies variability of animals, such as anatomy, physiology, pharmacokinetics, and pharmacodynamics. For this reason, studies in this area have become a highlight, since they are still scarce in comparison with those on human drug use. To overcome many limitations related to the bioavailability, efficacy, and safety of pharmacotherapy in animals, especially livestock and domestic animals, polymers-based drug delivery systems are promising tools if they guarantee greater selectivity and less toxicity in dosage forms. In addition, these tools may be developed according to the great interspecies variability. To contribute to these discussions, this paper provides an updated review of the major polymer-based drug delivery systems projected for veterinary use. Traditional and innovative drug delivery systems based on polymers are presented, with an emphasis on films, microparticles, micelles, nanogels, nanoparticles, tablets, implants and hydrogel-based drug delivery systems. We discuss important concepts for the veterinarian about the mechanisms of drug release and, for the pharmacist, the advantages in the development of pharmaceutical forms for the animal population. Finally, challenges and opportunities are presented in the field of pharmaceutical dosage forms for veterinary use in response to the interests of the pharmaceutical industry.
Collapse
Affiliation(s)
- Suzana Gonçalves Carvalho
- School of Pharmaceutical Sciences, São Paulo State University, UNESP, Department of Drugs and Medicines, 14800-903 Araraquara, SP, Brazil.
| | - Amanda Letícia Polli Silvestre
- School of Pharmaceutical Sciences, São Paulo State University, UNESP, Department of Drugs and Medicines, 14800-903 Araraquara, SP, Brazil
| | - Aline Martins Dos Santos
- School of Pharmaceutical Sciences, São Paulo State University, UNESP, Department of Drugs and Medicines, 14800-903 Araraquara, SP, Brazil
| | - Bruno Fonseca-Santos
- Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), 13083-871 Campinas, SP, Brazil
| | - Winner Duque Rodrigues
- School of Pharmaceutical Sciences, São Paulo State University, UNESP, Department of Drugs and Medicines, 14800-903 Araraquara, SP, Brazil
| | - Maria Palmira Daflon Gremião
- School of Pharmaceutical Sciences, São Paulo State University, UNESP, Department of Drugs and Medicines, 14800-903 Araraquara, SP, Brazil.
| | - Marlus Chorilli
- School of Pharmaceutical Sciences, São Paulo State University, UNESP, Department of Drugs and Medicines, 14800-903 Araraquara, SP, Brazil.
| | - Janaína Cecília Oliveira Villanova
- Laboratory of Pharmaceutical Production, Department of Pharmacy and Nutrition, Federal University of Espirito Santo (UFES), 29500-000 Alegre, ES, Brazil.
| |
Collapse
|
5
|
Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma. Pharmaceutics 2021; 13:pharmaceutics13030362. [PMID: 33803276 PMCID: PMC8000699 DOI: 10.3390/pharmaceutics13030362] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/02/2021] [Accepted: 03/04/2021] [Indexed: 12/01/2022] Open
Abstract
Pleural mesothelioma is a lung diffuse tumor, whose complete resection is unlikely. Consequently, metastases reappear where the primary tumor was removed. This paper illustrates the orphan medicine designation procedure of an intracavitary cisplatin film and related pharmaceutical development aspects requested by the European Medicines Agency (EMA) in its Scientific Advice. Since cisplatin pharmacokinetics from the implanted film in sheep resulted substantially modified compared to intravenous administration, the formation of a cisplatin/hyaluronan complex had been hypothesized. Here, the interaction between sodium hyaluronate (NaHA) and cisplatin (CisPt) was demonstrated. Size exclusion chromatography qualitatively evidenced the complex in the film-forming mixture, only showing the NaHA peak. Atomic absorption spectroscopy of the corresponding fraction revealed platinum, confirming the interaction. Reverse phase HPLC quantified about 5% free cisplatin in the film-forming mixture, indirectly meaning that 95% was complexed. Finally, a study of CisPt release from the film assessed how CisPt/NaHA complex affected drug availability. In water, a medium without chloride ions, there was no release and the film remained intact for 48 h and longer, whereas the placebo film dissolved in 15 min. In 0.9% NaCl medium, the film became more soluble, dissolving within 3–4 h. However, cisplatin release was still controlled by the existing complex in solution until chloride ions displaced it. While the film modified its dissolution with aging, CisPt release remained unaffected (90% released in 48 h).
Collapse
|
6
|
Docetaxel-Loaded Poly(3HB- co-4HB) Biodegradable Nanoparticles: Impact of Copolymer Composition. NANOMATERIALS 2020; 10:nano10112123. [PMID: 33114572 PMCID: PMC7716210 DOI: 10.3390/nano10112123] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 10/17/2020] [Accepted: 10/22/2020] [Indexed: 01/10/2023]
Abstract
Polyhydroxyalkanoate (PHA) copolymers show a relatively higher in vivo degradation rate compared to other PHAs, thus, they receive a great deal of attention for a wide range of medical applications. Nanoparticles (NPs) loaded with poorly water-soluble anticancer drug docetaxel (DCX) were produced using poly(3-hydroxybutyrate-co-4-hydroxybutyrate), P(3HB-co-4HB), copolymers biosynthesised from Cupriavidus malaysiensis USMAA1020 isolated from the Malaysian environment. Three copolymers with different molar proportions of 4-hydroxybutirate (4HB) were used: 16% (PHB16), 30% (PHB30) and 70% (PHB70) 4HB-containing P(3HB-co-4HB). Blank and DCX-loaded nanoparticles were then characterized for their size and size distribution, surface charge, encapsulation efficiency and drug release. Preformulation studies showed that an optimised formulation could be achieved through the emulsification/solvent evaporation method using PHB70 with the addition of 1.0% PVA, as stabilizer and 0.03% VitE-TPGS, as surfactant. DCX-loaded PHB70 nanoparticles (DCX-PHB70) gave the desired particle size distribution in terms of average particle size around 150 nm and narrow particle size distribution (polydispersity index (PDI) below 0.100). The encapsulation efficiency result showed that at 30% w/w drug-to-polymer ratio: DCX- PHB16 NPs were able to encapsulate up to 42% of DCX; DCX-PHB30 NPs encapsulated up to 46% of DCX and DCX-PHB70 NPs encapsulated up to 50% of DCX within the nanoparticle system. Approximately 60% of DCX was released from the DCX-PHB70 NPs within 7 days for 5%, 10% and 20% of drug-to-polymer ratio while for the 30% and 40% drug-to-polymer ratios, an almost complete drug release (98%) after 7 days of incubation was observed.
Collapse
|
7
|
Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer. Int J Biol Macromol 2020; 160:128-141. [PMID: 32445818 DOI: 10.1016/j.ijbiomac.2020.05.146] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 05/05/2020] [Accepted: 05/18/2020] [Indexed: 02/07/2023]
Abstract
The purpose of this study was to design and evaluate chitosan dispersed lipid vesicles (chitosomes) as potential delivery carriers for repurposing metformin (Met) against malignant pleural mesothelioma. Chitosomes were prepared by directly hydrating the thin lipid film using chitosan solution as hydration medium, instead of using it as a coating agent. Developed chitosomes demonstrated spherical morphology, positive surface charge (~30 mV) and ~60% encapsulation efficiency. The calorimetric studies and X-ray diffraction pattern of Met-loaded chitosomes confirmed the successful encapsulation of Met inside the chitosome vesicles. Optimized chitosome formulation showed ~70% drug release in 72 h, displaying prolonged and controlled release of drug. Results demonstrated that Met encapsulated chitosomes possessed enhanced cellular internalization and improved cytotoxic potential. Our findings also supported inhibitory activity of chitosomes against metastatic property of pleural mesothelioma cells. The in-vitro tumor simulation studies further established anti-tumor activity of Met encapsulated chitosomes as supported by reduction in tumor volume and presence of minimal viable cells in tumor mass. The obtained results establish the effectiveness of chitosomes as delivery carrier for Met as treatment alternative for malignant pleural mesothelioma.
Collapse
|
8
|
Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, Petronini PG, Rusca M, Carbognani P, Ampollini L. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model. Eur J Pharm Sci 2018; 123:89-97. [PMID: 30030099 DOI: 10.1016/j.ejps.2018.07.035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 07/02/2018] [Accepted: 07/16/2018] [Indexed: 10/28/2022]
Abstract
Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by a long latency period of 20-50 years after exposure to the main aetiology agent that is asbestos. MPM treatments include surgery, chemotherapy, and radiation therapy, with the combination pemetrexed and cisplatin being the standard chemotherapy approach. Despite this multimodality therapy one of the major issues after surgery is the high rate of local recurrence of the tumor. One possible approach would be the intrapleural application of implants loaded with anticancer drug to be applied during surgery to prevent local tumor recurrence. The implant proposed in the present work is a polymeric film of hyaluronic acid loaded with pemetrexed. The film developed is a hydrophilic, thin and flexible film sufficiently resistant to be applied intrapleurally adhering to the mesothelial surface. The release of pemetrexed from the film was found to be complete within2 h in phosphate buffered saline. In an orthotopic model of mesothelioma recurrence in rats, pemetrexed loaded films showed the same antitumor efficacy of pemetrexed disodium solutions administered intravenously or intrapleurally, while when administered in combination with cisplatin-loaded hyaluronate film, the implants almost completely prevented tumor recurrence. The local administration of drug-loaded polymer implants appears an ideal chemotherapy strategy especially for patients in which surgery is already selected as a viable therapeutic option.
Collapse
Affiliation(s)
- Fabio Sonvico
- Biopharmanet-TEC, University of Parma, Parma, Italy; Department of Food and Drug, University of Parma, Parma, Italy.
| | - Stefano Barbieri
- Biopharmanet-TEC, University of Parma, Parma, Italy; Department of Food and Drug, University of Parma, Parma, Italy
| | - Paolo Colombo
- Department of Food and Drug, University of Parma, Parma, Italy; PlumeStars s.r.l., Parma, Italy
| | | | - Claudio Mucchino
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Italy
| | | | - Pier Giorgio Petronini
- Clinical and Experimental Medicine, Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Michele Rusca
- Thoracic Surgery, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - Paolo Carbognani
- Thoracic Surgery, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - Luca Ampollini
- Thoracic Surgery, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| |
Collapse
|